Dr. Martens’ (DOCS) “Buy” Rating Reaffirmed at Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of Dr. Martens (LON:DOCS) in a research report sent to investors on Tuesday morning, MarketBeat.com reports.

Separately, Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Dr. Martens currently has an average rating of “Moderate Buy” and a consensus price target of GBX 6,000.

Dr. Martens Price Performance

Shares of LON:DOCS opened at GBX 66.90 on Tuesday. Dr. Martens has a fifty-two week low of GBX 43.02 and a fifty-two week high of GBX 100.87. The business has a 50-day moving average of GBX 76.21 and a two-hundred day moving average of GBX 83.39. The stock has a market capitalization of £646.63 million, a P/E ratio of 39.35, a P/E/G ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13.

Dr. Martens (LON:DOCS) last issued its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. On average, equities research analysts predict that Dr. Martens will post 2.5809394 EPS for the current fiscal year.

Insider Buying and Selling

In other Dr. Martens news, insider Robert Hanson purchased 96,000 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was bought at an average cost of GBX 79 per share, for a total transaction of £75,840. Over the last quarter, insiders purchased 97,130 shares of company stock valued at $7,673,816. Insiders own 2.79% of the company’s stock.

Key Headlines Impacting Dr. Martens

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Berenberg Bank reaffirmed a “buy” rating on DOCS, which supports investor confidence in the brand and long-term growth potential. Broker Rating
• Negative Sentiment: Dr. Martens projected flat revenue for 2026 while saying it will scale back discounts — a move that should help margins but signals limited top-line growth near term, which is weighing on the share price. Revenue Guidance Article

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.